Literature DB >> 1138549

Cardiac conduction in myotonic dystrophy.

R C Griggs, R J Davis, D C Anderson, J T Dove.   

Abstract

Cardiac conduction abnormalities are frequent in myotonic dystrophy and can result in complete heart block. In a study of 26 patients with myotonic dystrophy, first degree heart block was found to precede clinical presentation of the disease in 7 patients. His bundle electrocardiography in 11 patients demonstrated abnormalities throughout the entire conducting system, even in patients with only first degree heart block. In patients with block of the right bundle branch or anterior fascicle of the left bundle branch, slowing in the remaining fascicles was always present. Therapy of myotonia with procainamide significantly lengthened the P-R interval, and treatment with diphenylhydantoin significantly shortened the P-R interval suggesting that diphenylhydantoin may be preferable for therapy of myotonia in patients with myotonic dystrophy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138549     DOI: 10.1016/0002-9343(75)90319-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Is it possible to identify infrahissian cardiac conduction abnormalities in myotonic dystrophy by non-invasive methods?

Authors:  D Babuty; L Fauchier; D Tena-Carbi; P Poret; J Leche; M Raynaud; J P Fauchier; P Cosnay
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 2.  Electrocardiographic abnormalities in patients with myotonic dystrophy.

Authors:  R C Florek; D W Triffon; D E Mann; S P Ringel; M J Reiter
Journal:  West J Med       Date:  1990-07

3.  Electrocardiographic findings in myotonic dystrophy.

Authors:  B O Olofsson; H Forsberg; S Andersson; P Bjerle; A Henriksson; I Wedin
Journal:  Br Heart J       Date:  1988-01

4.  Nifedipine in the treatment of myotonia.

Authors:  A H Bretag
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

5.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

6.  QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance.

Authors:  Saman Nazarian; David A Bluemke; Kathryn R Wagner; Menekhem M Zviman; Evrim Turkbey; Brian S Caffo; Monda Shehata; David Edwards; Barbara Butcher; Hugh Calkins; Ronald D Berger; Henry R Halperin; Gordon F Tomaselli
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

7.  Intracardiac conduction defects in dystrophia myotonica. Electrophysiological study of 12 cases.

Authors:  M Komajda; R Frank; J Vedel; G Fontaine; J C Petitot; Y Grosgogeat
Journal:  Br Heart J       Date:  1980-03

8.  Respiratory failure and cardiac disturbances in myotonic dystrophy.

Authors:  M de Backer; P Bergmann; A Perissino; P Gottignies; R J Kahn
Journal:  Eur J Intensive Care Med       Date:  1976-09

9.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

10.  Myotonia induced with clofibrate in rats.

Authors:  H Kwieciński
Journal:  J Neurol       Date:  1978-10-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.